IL-15 (human) (rec.) (His)

CHF 190.00
In stock
CHI-HR-20015-C01010 µgCHF 190.00
CHI-HR-20015-C05050 µgCHF 520.00
More Information
Product Details
Synonyms Interleukin-15
Product Type Protein
Source/Host E. coli

The extracellular domain of human IL-15 (aa 49-162) is fused at the C-terminus to a His-tag.

Crossreactivity Human
Biological Activity

Measured by its ability to stimulate the proliferation of mouse CTLL-2 cells. The ED50 for this effect is typically 0.5ng/mL, corresponding to a specific activity of 2x 106 units/mg

MW ~14kDa (SDS-PAGE)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.1EU/μg protein (LAL test; Lonza).
Reconstitution Reconstitute 10µg vial with 100 µl sterile water to a concentration of 0.1mg/ml.
Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml.
Add 1X PBS to the desired protein concentration.
Accession Number P40933
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Other Product Data

NCBI reference P40933: IL-15 (human)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Rα, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.